Skip to main content

Vifor Pharma Pty Ltd

Regulatory activities for this sponsor.

Sponsor content

24 result(s) found, displaying 1 to 10
  • AusPAR: Korsuva

    AusPAR for Korsuva (difelikefalin) is approved to treat moderate-to-severe pruritus associated with chronic kidney disease in adults on haemodialysis.
  • AusPAR: Tavneos

    AusPAR for Tavneos (avacopan) in combination with a rituximab or cyclophosphamide based regimen for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis
  • Tavneos

    TGA decision: Tavneos (avacopan) is approved to treat adults with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]).
  • Korsuva

    Korsuva (difelikefalin acetate) is approved to treat chronic kidney disease

Help us improve the Therapeutic Goods Administration site